Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Abstract: A calibration device is provided for a weighing system that has a tank with a plurality of support legs at a lower part thereof. The calibration device has at least one calibration module, a hydraulic system and a calibration terminal. An upper end of each calibration module is connected to an upper part of a corresponding support leg. A lower end of each calibration module is fixed to a foundation. A hose connects each calibration module to the hydraulic system for applying a force to the tank. The calibration terminal, connected to each calibration module, displays in real-time, the force applied to the tank. The calibration device can greatly improve the production efficiency, and in use, takes only two hours to complete the calibration, which is faster than the test weight and other calibration methods.

Abstract: A downhole throttling device based on wireless control includes an inlet nozzle, a throttling assembly, an electrical sealing cylinder, a gas guide cylinder, a lower adapter sleeve, an end socket, a female sleeve, and electrical components. The inlet nozzle is connected to the throttling assembly, the throttling assembly is connected to the electrical sealing cylinder and the gas guide cylinder, the electrical sealing cylinder and the gas guide cylinder are both connected to the lower adapter sleeve, the lower adapter sleeve is respectively connected to the end socket and the female sleeve, and the electrical components are arranged in the electrical sealing cylinder. A throttling effect is achieved by detecting the temperature and pressure in a tube by a temperature/pressure sensor in the electrical components and controlling a motor to rotate a movable valve in the throttling assembly by a circuit control assembly, thereby achieving wireless control over downhole throttling.

Abstract: An anti-FGFR2 antibody, an encoding nucleic acid of the antibody, a vector and host cell for the expression and production thereof, an antibody-drug conjugate, and a pharmaceutical composition comprising the antibody. The present invention further relates to the use of the antibody molecule in a drug for diagnosing a cancer caused by FGFR2-pathway-related dysregulation, and the use of the antibody or antibody-drug conjugate in the preparation of a medicament for treating a cancer caused by FGFR2-pathway-related dysregulation, in particular gastric cancer.

Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors.

Abstract: The preparation method includes steps of (1) melting steel according to in weight percentage 0.001-0.003% of C, 5.0-6.6% of Si, 0.2-0.3% of Mn, 0.05-0.12% of Al, 0.01-0.04% of V, 0.03-0.06% of Nb, 0.02-0.03% of S, 0.009-0.020% of N, O which is less than or equal to 0.0020%, and the balance being Fe and unavoidable impurities; (2) forming cast strips after a thin-strip casting course; (3) hot-rolling the cast strips under inert atmosphere conditions; (4) cooling the hot-rolled cast strips to 550-600 DEG C., coiling and performing low-temperature hot rolling/warm rolling on the coiled cast strips under a nitrogen atmosphere condition; (5) removing oxidized scales though pickling, performing cold rolling multiple times; (6) performing recrystallization annealing, coating with an MgO layer, and coiling; (7) performing purification annealing under hydrogen circulation conditions; and (8) removing oxidized scales, coating with an insulating layer, performing flat stretch annealing, and air-cooled coiling.

Abstract: A message forwarding method and system, and a relay agent device, where the forwarding method includes receiving a first dynamic host configuration protocol (DHCP) for Internet Protocol (IP) version 6 (DHCPv6) message from a DHCPv6 client through a layer-3 interface, generating a relay-forward message, where the first DHCPv6 message is encapsulated into the relay-forward message and an identifier (ID) of the layer-3 interface is added therein, and sending the relay-forward message to a DHCPv6 server.

Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age.

Abstract: A message forwarding method and system, and a relay agent device, where the forwarding method includes receiving a first dynamic host configuration protocol (DHCP) for Internet Protocol (IP) version 6 (DHCPv6) message from a DHCPv6 client through a layer-3 interface, generating a relay-forward message, where the first DHCPv6 message is encapsulated into the relay-forward message and an identifier (ID) of the layer-3 interface is added therein, and sending the relay-forward message to a DHCPv6 server.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes receiving a first dynamic host configuration protocol (DHCP) for Internet Protocol (IP) version 6 (DHCPv6 ) message from a DHCPv6 client through a layer-3 interface, generating a relay-forward message, where the first DHCPv6 message is encapsulated into the relay-forward message and an identifier (ID) of the layer-3 interface is added therein, and sending the relay-forward message to a DHCPv6 server.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes: receiving a first DHCPv6 message from a DHCPv6 client through a layer-3 interface; generating a Relay-forward message, where the first DHCPv6 message is encapsulated into the Relay-forward message and an identifier of the layer-3 interface is added therein; and sending the Relay-forward message to a DHCPv6 server.

Abstract: The preparation method includes steps of (1) melting steel according to in weight percentage 0.001-0.003% of C, 5.0-6.6% of Si, 0.2-0.3% of Mn, 0.05-0.12% of Al, 0.01-0.04% of V, 0.03-0.06% of Nb, 0.02-0.03% of S, 0.009-0.020% of N, O which is less than or equal to 0.0020%, and the balance being Fe and unavoidable impurities; (2) forming cast strips after a thin-strip casting course; (3) hot-rolling the cast strips under inert atmosphere conditions; (4) cooling the hot-rolled cast strips to 550-600 DEG C, coiling and performing low-temperature hot rolling/warm rolling on the coiled cast strips under a nitrogen atmosphere condition; (5) removing oxidized scales though pickling, performing cold rolling multiple times; (6) performing recrystallization annealing, coating with an MgO layer, and coiling; (7) performing purification annealing under hydrogen circulation conditions; and (8) removing oxidized scales, coating with an insulating layer, performing flat stretch annealing, and air-cooled coiling.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes receiving a first dynamic host configuration protocol (DHCP) for Internet Protocol (IP) version 6 (DHCPv6 ) message from a DHCPv6 client through a layer-3 interface, generating a relay-forward message, where the first DHCPv6 message is encapsulated into the relay-forward message and an identifier (ID) of the layer-3 interface is added therein, and sending the relay-forward message to a DHCPv6 server.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes: receiving a first DHCPv6 message from a DHCPv6 client through a layer-3 interface; generating a Relay-forward message, where the first DHCPv6 message is encapsulated into the Relay-forward message and an identifier of the layer-3 interface is added therein; and sending the Relay-forward message to a DHCPv6 server.

Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age.

Abstract: Provided is a method for screening microRNAs with gene silencing function at both transcriptional and post-transcriptional levels. The microRNA obtained via the screening method can down-regulate the expression of mRNA of a target gene by binding to a specific site of 5?-flanking region of the target gene, and also down-regulate the expression of the protein of the target gene by binding to a specific site of the 3?-untranslated region of the target gene. Also provided are microRNAs obtained via the screening method, the use of the same in gene silencing, and a method of gene silencing by using the same.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes: receiving a first DHCPv6 message from a DHCPv6 client through a layer-3 interface; generating a Relay-forward message, where the first DHCPv6 message is encapsulated into the Relay-forward message and an identifier of the layer-3 interface is added therein; and sending the Relay-forward message to a DHCPv6 server.

Abstract: The present disclosure provides a message forwarding method and system, and a relay agent device. The forwarding method includes: receiving a first DHCPv6 message from a DHCPv6 client through a layer-3 interface; generating a Relay-forward message, where the first DHCPv6 message is encapsulated into the Relay-forward message and an identifier of the layer-3 interface is added therein; and sending the Relay-forward message to a DHCPv6 server.

Abstract: An apparatus, system and method for forwarding user plane data. A user plane gateway (102) comprises: a receiving module (106) for receiving data which comes from a first network element (100) and uses a first transfer module; a converting module (108) for converting the transfer mode of the received data from the first transfer mode to a second transfer mode, wherein the first transfer mode is asynchronous transfer mode (ATM) and the second transfer mode is Internet Protocol (IP) transfer mode, or the first transfer mode is IP transfer mode and the second transfer mode is ATM; and a sending module (110) for sending the converted data to a second network element (104) using the second transfer mode. This apparatus, system and method achieve the effects that the aggregation of ATM network to the IP network, the networking device able to be compatible forwardly, improving bandwidth utilization rate, saving costs, etc.

Abstract: Use of cell autophagy (type II cell apoptosis) inhibitors for preventing and/or treating avian influenza, injury of lungs caused by avian influenza virus or nanometer materials. The cell autophagy (type II cell apoptosis) inhibitors are selected from 3-methyladenine, SB203580, LY294002, and or wortmannin. The injury of lungs includes acute respiratory distress syndrome. The avian influenza virus is H5N1, H5N2 or H9N2 avian influenza virus. The nanometer materials include PAMAM G3, G4, G5, G5.5, G6, G7, or G8.